Qube Research & Technologies LTD Atai Life Sciences N.V. Transaction History

Qube Research & Technologies LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$1.5 - $2.19 $116,907 - $170,684	-77,938 Reduced 60.65%	50,556 $99,000
Q4 2023 Feb 13, 2024	BUY	$1.04 - $1.55 $105,252 - $156,866	101,204 Added 370.85%	128,494 $181,000
Q3 2023 Nov 13, 2023	SELL	$1.27 - $2.28 $10,701 - $19,211	-8,426 Reduced 23.59%	27,290 $35,000
Q2 2023 Aug 14, 2023	BUY	$1.44 - $2.19 $15,461 - $23,514	10,737 Added 42.98%	35,716 $61,000
Q1 2023 May 15, 2023	BUY	$1.17 - $2.7 $29,225 - $67,443	24,979 New	24,979 $45,000
Q3 2022 Nov 14, 2022	SELL	$3.14 - $4.87 $898 - $1,392	-286 Reduced 2.51%	11,086 $37,000
Q2 2022 Aug 15, 2022	BUY	$3.03 - $5.32 $790 - $1,388	261 Added 2.35%	11,372 $41,000
Q1 2022 May 09, 2022	BUY	$4.66 - $7.66 $51,777 - $85,110	11,111 New	11,111 $57,000

12.8M

9.2K

118K

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $234M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.